Dallas-based Slotnik Capital acquired 635,000 shares of STAAR Surgical, adding an estimated $17.06 million position. The transaction resulted in a position representing 5.33% of Slotnik Capital's 13F AUM.
Lancer Orthodontics (OTCMKTS:LANZ - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Profitability This table compares Lancer Orthodontics and STAAR
London-based Sand Grove Capital Management acquired 829,123 shares of STAAR Surgical Company in the third quarter. The position was worth about $22.28 million at quarter-end.
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) has been given a consensus rating of "Reduce" by the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have assigned a hold recommendation to the company. The average 1 year price
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth postponement of STAAR's Special Meeting of Shareholders (the “Special Meeting”) in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). The Special Meeting, which was originally scheduled to be held on October 23, 2.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the “Special Meeting”). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to Janua.
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappointment in the Company's Board of Directors' (the "Board") continued pursuit of the deal: As shareholders of STAAR Surgical for the past decade, we remain convicted in the long-term potential of the Company and are disappointed that the Board has continued to pursue the ill-advised sale to Alcon, which we do not believe is in the best interests of STAAR shareholders and does not represent adequate value for the Company.
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to urge its fellow shareholders to vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Shareholders can find additional information at www.LetSTAARS.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockholders: Dear STAAR Surgical Stockholders: The Special Meeting of Stockholders to vote on the amended agreement with Alcon Inc. (SIX/NYSE: ALC) is just days away. How you vote at the Special Meeting will greatly influence the value of your shares. Yo.
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) regarding the proposed acquisition of STAAR by Alcon Inc. (“Alc.
